WO1991014448A1 - New proteins, peptides and corresponding dna or rna sequences and probes useful for diagnosing tuberculosis - Google Patents
New proteins, peptides and corresponding dna or rna sequences and probes useful for diagnosing tuberculosis Download PDFInfo
- Publication number
- WO1991014448A1 WO1991014448A1 PCT/SE1991/000225 SE9100225W WO9114448A1 WO 1991014448 A1 WO1991014448 A1 WO 1991014448A1 SE 9100225 W SE9100225 W SE 9100225W WO 9114448 A1 WO9114448 A1 WO 9114448A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tuberculosis
- protein
- human
- diagnosis
- kda
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 84
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 64
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 title claims description 34
- 108090000623 proteins and genes Proteins 0.000 title claims description 34
- 239000000523 sample Substances 0.000 title claims description 16
- 238000003745 diagnosis Methods 0.000 claims abstract description 29
- 238000001514 detection method Methods 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 11
- 210000001124 body fluid Anatomy 0.000 claims description 11
- 239000010839 body fluid Substances 0.000 claims description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 10
- 239000003298 DNA probe Substances 0.000 claims description 9
- 210000004910 pleural fluid Anatomy 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 206010036790 Productive cough Diseases 0.000 claims description 7
- 210000003802 sputum Anatomy 0.000 claims description 7
- 208000024794 sputum Diseases 0.000 claims description 7
- 108020004518 RNA Probes Proteins 0.000 claims description 6
- 239000003391 RNA probe Substances 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 5
- 230000006052 T cell proliferation Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 108020003215 DNA Probes Proteins 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 238000003118 sandwich ELISA Methods 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 4
- 238000009396 hybridization Methods 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 238000001516 cell proliferation assay Methods 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000405 serological effect Effects 0.000 claims 1
- 102000036639 antigens Human genes 0.000 abstract description 101
- 108091007433 antigens Proteins 0.000 abstract description 101
- 239000000427 antigen Substances 0.000 abstract description 98
- 101710159910 Movement protein Proteins 0.000 abstract description 24
- 102100024147 Protein phosphatase 1 regulatory subunit 14A Human genes 0.000 abstract description 24
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 12
- 238000002965 ELISA Methods 0.000 abstract description 9
- 150000001413 amino acids Chemical class 0.000 abstract description 8
- 238000013399 early diagnosis Methods 0.000 abstract description 6
- 230000027455 binding Effects 0.000 abstract description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- 238000009169 immunotherapy Methods 0.000 abstract description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 2
- 230000000984 immunochemical effect Effects 0.000 abstract description 2
- 230000002297 mitogenic effect Effects 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 11
- 241000304886 Bacilli Species 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000007079 Peptide Fragments Human genes 0.000 description 6
- 108010033276 Peptide Fragments Proteins 0.000 description 6
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 208000022971 Tuberculous meningitis Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000003277 amino acid sequence analysis Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 208000001223 meningeal tuberculosis Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 101710097814 13 kDa protein Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 101100306081 Arabidopsis thaliana RPK1 gene Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 101100287598 Colletotrichum orbiculare (strain 104-T / ATCC 96160 / CBS 514.97 / LARS 414 / MAFF 240422) PKAR gene Proteins 0.000 description 1
- 241000992414 Drechslera phlei Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010027259 Meningitis tuberculous Diseases 0.000 description 1
- 101710164418 Movement protein TGB2 Proteins 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100238379 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MPS1 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000829189 Staphylococcus aureus Glutamyl endopeptidase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011842 forensic investigation Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Definitions
- the 17 kDa protein antigen which has an N-terminus of A T T L P V Q R (aa 1-8) has atleast three specific antibody binding epitopes located on linear peptides of sequences, R A T Y D K R Y E V R (aa 91-101) and S E F A Y G S F V R (aa 68-77) which were useful in a micro ELIS ⁇ for the early diagnosis of human tuberculosis by the detection of specific antibodies.
- the 17 kDa protein antigen which was mitogenic for human tuberculous peripheral blood lymphocytes was found to carry three predicted T-cell epitopes on linear peptides of sequences, S E F A Y G S F V R (aa 68-77) and A E L P G V D P D C D V C I T R (aa 107-122) .
- the 17 kDa antigen of WL_ tuberculosis (SII 1) which thus had both B and T cell reactive properties was found to contain 131 amino acids and potentially applicable in the immuno diagnosis, immuno therapy and immuno prophylaxis of human tuberculosis.
- the present invention relates to a novel 17 kDa protein antigen of Kycobacterium tuberculosis (South Indian Isolate SII 1) and certain peptide fragments derived therefrom, and to the use of the said antigen, and of the peptide fragments
- the invention also relates to the DNA sequence coding for the said 17 kDa antigen, to DNA sequences coding for the said peptide fragments derived from the 17 kDa antigen and to the DNA and RNA probes constructed on the basis of the protein sequence of the 17 kDa antigen including the sequences of the peptide fragments of the 17 kDa antigen.
- a major field of use is the use of 17 kDa antigen and peptide fragments thereof in immuno diagnosis of tuberculosis.
- a further field of use is the use of the 17 kDa antigen or of the said peptide sub structures thereof for the preparation of a vaccine against tuberculosis.
- a further field of use is the use of the 17 kDa antigen or its sub structure peptides for the detection of T cell proliferation by skin tests or invitro tests in man. This last mentioned field of use is of importance in the possible treatment of human cancer by the boosting of cellular immunity.
- a further field of use is the use of the 17 kDa antigen or its sub structure peptides for the laboratory production of cellular growth factors and enzymes.
- SUBSTITUTE SHEET countries has posed a problem of secondary infection with ycobacteria including M.tuberculosis.
- tuberculous specimen is not easy under field conditions and atlea ⁇ t 10 4 bacilli/ml are required for effective screening.
- Many tuberculous specimens like cerebro spinal fluids from tuberculous meningitis infrequently contain bacilli.
- bacteriological culture generally
- SUBSTITUTESHEET takes 6 to 8 weeks and is expensive as a routine diagnostic measur .
- tuberculin skin test lacks sensitivity and specificity and takes about 3 days for completion. Since chemotherapy of TB requires compliance for atleast 6 months, many patients who are irregular in treatment develop drug resistance and transmit live bacilli. Finally, the traditional 3CG vaccination has now been found to give varying levels of protection depending upon geographic regions.
- Mycobacteria are powerful iamunogens * for man and aniaal ⁇ , as evidenced by their use in immuno adjuvants to boost iaaune responses.
- many antigens derived from M.tuberculosis have been known to induce the formation of specific antibodies and proliferative lymphocytes among TB patients (Ivanyi et al., 1988) and experimental animal models.
- the detection of an antibody response in TB has a potential application in early diagnosis.
- the study of M.tuberculosis specific T lymphocytes has application in early diagnosis by skin tests and development of protective vaccines.
- Table I M.tuberculosis protein antigens identified by N-terminal amino acid sequences.
- An ELISA kit for diagnosing TB using A60 antigen present in all mycobacteria has been introduced by ANDA diagnostics (France) . The test is thus not specific for human TB alone.
- Phenotypic variation in virulence is known among the M.tuberculosis strains isolated in South India (Naganathan et al 1987), the molecular basis for which is not yet established. Abou Zeid et al, (1988) found that a 13 kDa protein antigen was present in phage type II virulent
- a 17 kDa protein antigen was found to be present among the isolates of M.tuberculosis.
- the i ⁇ muno chemical features of this antigen are disclosed under this invention.
- the 17 kDa protein antigen of M.tuberculosis (SII 1) as defined below and certain sub structures (peptides) of 17 kDa protein antigen as defined below.
- SUBSTITUTESHEET 6 The use of the 17 kDa protein antigen or sub structures (peptides) thereof for the treatment of tuberculosis.
- DNA or RNA probes constructed on the basis of the protein sequence of the 17 kDa antigen or sub structures (peptides) thereof for diagnosis of tuberculosis.
- Such probes can be constructed by methods known in the art. Labelling of such probes can be done by known methods such as radioisotope incorporation or by non radio-active labelling use for example, biotin.
- a method for diagnosis of human tuberculosis by interacting a body fluid such as serum from a patient to be diagnosed with a 17 kDa protein as defined in paragraph 5 above.
- a method for in vitro detection of human tuberculosis which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a monoclonal antibody as defined in paragraph 10 in labelled form.
- a method for in vitro detection of human tuberculosis which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a monoclonal antibody as defined in paragraph 10 in labelled form.
- a method for in vitro detection of human tuberculosis which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a polyclonal antibody as defined in paragraph 3 in labelled form.
- a micro organism expressing a 17 kDa protein or sub structures thereof as disclosed in paragraph 1 above.
- a vaccine against tuberculosis developed on the basis of the 17 kDa antigen or sub structure peptides thereof as disclosed in paragraph 1 above.
- Such a vaccine can be a product of genetically engineered organisms such as Salmonella, Vaccinia virus etc.
- the present invention is exemplified by but not limited to the diagnosis, therapy or prophylaxis of diseases, especially diagnosis of M.tuberculosis infection.
- Epidemiological screening, forensic investigations, determination of food contaminations, public health surveys, preventive medicine, veterinary and agricultural applications with regard to the diagnosis of infectious agents may be covered by this disclosure.
- Fig. 1 shows the HPLC profile of 17 kDa antigen.
- Tryptic map 30 ug of 17 kDa protein was digested with TPCK treated trypsin with an enzyme to substrate ratio of 1:50 in o 0.1 M ammonium bicarbonate buffer, pH 7.8 at 37 C for 5 h.
- the tryptic digest was fractionated by HPLC on RP 18 column (0.46 x 25 cm) equilibrated with solvent A (0.1% TFA in water) and the peptides were eluted with a gradient of solvent B (70% acetonitrile containing 0.085% TFA) from 0 to 65% in 60 ain.
- solvent B 70% acetonitrile containing 0.085% TFA
- V8 protease aap 30 ug of 17 kDa antigen was treated with o staphylococcal V8 protease for 48 h in 0.07% ammonia at 37
- the molar ratio of the enzyme to substrate was 1:25.
- the various peptides in the enzyme digest were purified on an
- the peptide profile is shown in Fig. 3.
- the amino acid sequence analysis of the protein and the peptide was done using protein sequencer model 77A (Applied Biosy ⁇ tems Inc., USA) with an on line PTH amino acid analyser.
- the sample was solubilized in 10% formic acid and fixed onto a polybrene coated (1 g) TFA treated glass fibre disc and used for sequencing.
- the first 18 amino acids from the N-terminal was determined using the whole protein. Based on the amino acid sequences of the tryptic peptides, V8 protease was selected to generate the peptides that could give the overlaps for the tryptic peptides. The alignment of both tryptic and V8 protease peptides gave the complete sequence for the 17 kDa antigen. The details of the overlaps are given in Fig. 4.
- the protein has A9, C3, Dll, E10, F9, G8, H2, 17, K4, Lll, M2, P9, Q2, R12, 88, T9, Vll and Y4. It is significant in not having tryptophan and a ⁇ paragine.
- the protein is acidic in nature since it has 5 acidic aain acids (D+E-21) in excess of the total number of basic aaino acids (R+K-16) .
- the protein has 131 aaino acids that account for a molecular weight of 14,762.
- M. tuberculosis (SII 1) , M. tuberculosis ATCC 27294, H.phlei, M ⁇
- FICA Freund's incomplete adjuvant
- this experiment confirms that a polyclonal or monoclonal antibody can be produced in the mouse which recognize the protein structure of 17 kDa antigen or sub structures (peptides) thereof.
- Such antibodies in particular the monoclonal antibodies can be used in an antigen detection method like the sandwich ELISA for the detection of the 17 kDa antigen or sub structures thereof among human tuberculosis specimen leading to immuno diagnosis of tuberculosis.
- Sera derived from 24 healthy persons and 20 culture proven TB patients were titrated against the 17 kDa antigen as follows.
- PVC Dynatech plates were coated with 1 ug/ l PBS of electro o eluted 17 kDa antigen for 24 h at 22 C.
- PBS-BSA blocked plates were then titrated against duplicate (1/200) dilutions o of sera which were incubated at 22 C for 2.5 h. Washed plates received anti human IgG HRP conjugate for 1.5 h.
- Washed plates were then assayed with O-phenylene diamine substrate and read at 492 na.
- Table II shows that the 17 kDa antigen had a sensitivity of 70% and specificity of 85%
- Sensitivity Known positivity among TB patients
- Specificity Known negativity among healthy controls
- ELISA + OD 492 n >-0.3 at 1/200 dilation (-mean + 2SD of OD 492 na for healthy controls, n-24].
- M.tuberculosis strains can be used in a micro ELISA system for the immuno diagnosis of tuberculosis in man.
- the peptides YEVR and ATYDK were mutually inhibitive thus indicating that they were a part of a complete antibody epitope, which was confirmed also by the determination of the complete structure of the 17 kDa antigen as in section 5.2.2, Fig 4.
- the other four _peptides were linear and probably conformational in the presentation of the antibody epitope.
- the peptides of the following aaino acid sequences were synthesized by solid phase aethod of
- RATYDKRYEVR Sensitivity 65%; Specificity 95%
- SEFAYGSFVR Sensitivity 66%; Specificity 95*
- the antibody epitope mapping as described has thus indicated that defined sub structures or peptides of 17 kDa antigen can be synthesized and used for the immunodiagnosis of human tuberculosis in micro ELISA.
- the peptide of the sequence RATYDKRYEVRDFDGRAEL was synthesized and found to have a sensitivity of 86.6% and a specificity of 100% when tested on CSF samples from culturtproven TBM patients and controls. This peptide is accordingly particularly suitable for use in place of the 17 kDa antigen in the ELISA test. 5.3.5 Demonstration that 17 kDa antigen is lympho proliterative
- PBL Peripheral blood lymphocytes
- T cell stimulatory epitopes were located on peptides of the following sequences: SEFAYGSFVR AELPGVDPDCDVCITK
- the 17 kDa antigen or sub structures can te used to stimulate human peripheral blood lymphocytes. Since stimulated lymphocytes elaborate several cellular growth and differentiation factors which contribute to the vaccine effect of 17 kDa antigen or its sub structures, the 17 kDa antigen can be used at the first instance as a vaccine against TB and also for non- specifically boosting cellular immunity.
- Figure 6 shows the primary structure of the 17 kDa antigen from M.tuberculosis containing the biologically active regions, although similar activity need not be ruled out in the unmarked regions.
- the present invention describes the immunoche ical properties of a novel 17 kDa protein antigen from M.tuberculosis (SII 1 strain) .
- M.tuberculosis causes tuberculosis worldwide aaong 16 million people. Because of inadequacy of the diagnostic procedures available now the disease has not yet been eradicated.
- the focus of research in recent years has been the development of immuno diagnostic methods for detecting TB at an early stage as well identification of suitable candidates for vaccination since the traditional BCG vaccine has given only a partial protection against TB.
- SUBSTITUTE SHEET SEFAYGSFVR which carried antibody binding epitopes for diagnosis of TB. Further, it contained two peptides which carried predicted T cell stimulating regions in sequences, SEFAYGSFVR and AELPGVDPDCDVCITR. The latter two peptides presumably contributed to the T cell stimulating property of the whole 17 kDa antigen described in this invention. The T cell stimulating property of the 17 kDa antigen and its sub structure peptides means that they could be used in therapy and vaccination for TB. 7. Figure legends.
- Fig. 1 HPLC analysis of the electro eluted 17 kDa protein antigen from M. tuberculosis (SII 1).
- HPLC conditions RP 18 column (LKB, 10 um pore size), A: 0.1% TFA in water, B: 0.085% TFA in 70% aceto nitrile, Gradient: 0 to 65% B in 40 min. Sensitivity: 0.08,220 nm.
- Fig. 2 Tryptic peptides of 17 kDa protein antigen from
- SII 1 M.tuberculosis (SII 1) fractionated by HPLC on RP 18 (LKB,10 um pore size).
- Amino acid sequence Sequence determined are drawn against each peptide.
- FIG. 3 V8 protease peptides of 17 kDa protein antigen from M.tuberculosis (SII 1) fractionated by HPLC on RP 18 (LKB, pore size 10 um) .
- Trp M.tuberculosis (SII 1) showing the alignment of peptides. Trp:
- SUBSTITUTE SHEET arrows denote the amino acid sequence obtained with the whole protein.
- AA 68 to 77 Antibody and T cell epitopes present.
- AA 91 to 101 Antibody epitope present.
- AA 107 to 122 Two T cell epitopes present.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Disclosed are the immunochemical properties of a 17 kDa protein antigen fractionated, purified and sequenced for amino acids from Mycobacterium tuberculosis (South Indian isolate, SII 1) which causes human tuberculosis worldwide among 16 million patients. The 17 kDa protein antigen which has an N-terminus of A T T L P V Q R (aa 1-8) has at least three specific antibody binding epitopes located on linear peptides of sequences, R A T Y D K R Y E V R (aa 91-101) and S E F A Y G S F V R (aa 68-77) which were useful in a micro ELISA for the early diagnosis of human tuberculosis by the detection of specific antibodies. The 17 kDa protein antigen which was mitogenic for human tuberculous peripheral blood lymphocytes was found to carry three predicted T-cell epitopes on linear peptides of sequences, S E F A Y G S F V R (aa 68-77) and A E L P G V D P D C D V C I T R (aa 107-122). The 17 kDa antigen of M. tuberculosis (SII 1) which thus had both B and T cell reactive properties was found to contain 131 amino acids and potentially applicable in the immuno diagnosis, immuno therapy and immuno prophylaxis of human tuberculosis.
Description
NEW PROTEINS , PEPTIDES AND CORRESPONDING DNA OR RNA SEQUENCES AND PROBES USEFUL FOR DIAGNOSING TUBERCULOSIS.
1. Summary of the invention
Disclosed are the immunochemical properties of a 17 kDa protein antigen fractionated, purified and seguenced for amino acids from Mycobacterium tuberculosis (South Indian isolate, SII 1) which causes human tuberculosis worldwide among 16 million patients. The 17 kDa protein antigen which has an N-terminus of A T T L P V Q R (aa 1-8) has atleast three specific antibody binding epitopes located on linear peptides of sequences, R A T Y D K R Y E V R (aa 91-101) and S E F A Y G S F V R (aa 68-77) which were useful in a micro ELISλ for the early diagnosis of human tuberculosis by the detection of specific antibodies. The 17 kDa protein antigen which was mitogenic for human tuberculous peripheral blood lymphocytes was found to carry three predicted T-cell epitopes on linear peptides of sequences, S E F A Y G S F V R (aa 68-77) and A E L P G V D P D C D V C I T R (aa 107-122) . The 17 kDa antigen of WL_ tuberculosis (SII 1) which thus had both B and T cell reactive properties was found to contain 131 amino acids and potentially applicable in the immuno diagnosis, immuno therapy and immuno prophylaxis of human tuberculosis.
2. Field of invention
The present invention relates to a novel 17 kDa protein antigen of Kycobacterium tuberculosis (South Indian Isolate SII 1) and certain peptide fragments derived therefrom, and to the use of the said antigen, and of the peptide fragments
SUBSTITUTE SHEET
derived therefrom, in immuno diagnosis, immunotherapy and immuno prophylaxis of human and experimental tuberculosis. The invention also relates to the DNA sequence coding for the said 17 kDa antigen, to DNA sequences coding for the said peptide fragments derived from the 17 kDa antigen and to the DNA and RNA probes constructed on the basis of the protein sequence of the 17 kDa antigen including the sequences of the peptide fragments of the 17 kDa antigen. A major field of use is the use of 17 kDa antigen and peptide fragments thereof in immuno diagnosis of tuberculosis. A further field of use is the use of the 17 kDa antigen or of the said peptide sub structures thereof for the preparation of a vaccine against tuberculosis. A further field of use is the use of the 17 kDa antigen or its sub structure peptides for the detection of T cell proliferation by skin tests or invitro tests in man. This last mentioned field of use is of importance in the possible treatment of human cancer by the boosting of cellular immunity. A further field of use is the use of the 17 kDa antigen or its sub structure peptides for the laboratory production of cellular growth factors and enzymes.
3. Background of invention
Human tuberculosis caused by K.tuberculosis is an important chronic debilitating disease occuring worldwide affecting about 16 million people. While it is prevalent mostly in under developed and developing countries, the recent epidemic of Acquired Immuno Deficiency Syndrome (AIDS) among developed
SUBSTITUTE SHEET
countries has posed a problem of secondary infection with ycobacteria including M.tuberculosis.
Precise and confirmative diagnosis of huaan TB enables early treatment for which powerful antibiotics are available, although in many countries drug resistance has become a problem. Nevertheless, early diagnosis of TB means effective chemotherapy and thus elimination of the transmission of live bacilli from pulmonary TB patients.
Conventional diagnosis of TB depends upon the clinical and radiological findings, microscopy of tuberculous specimen for bacilli, and bacteriological isolation in culture of M.tuberculosis.
Global control of TB has not yet been established because of the inadequacy of the presently available methods of diagnosis.
Thus many clinical features of TB are not specific to TB alone and a study in India (source: National Tuberculosis Institute, Bangalore, India) revealed that only 30% of the X-ray suspects eventually developed TB although, in many1 countries including India, all X-ray suspects are put on anti tuberculous chemotherapy.
The microscopy of tuberculous specimen is not easy under field conditions and atleaβt 104bacilli/ml are required for effective screening. Many tuberculous specimens like cerebro spinal fluids from tuberculous meningitis infrequently contain bacilli. Further, bacteriological culture generally
SUBSTITUTESHEET
takes 6 to 8 weeks and is expensive as a routine diagnostic measur .
The widely used tuberculin skin test lacks sensitivity and specificity and takes about 3 days for completion. Since chemotherapy of TB requires compliance for atleast 6 months, many patients who are irregular in treatment develop drug resistance and transmit live bacilli. Finally, the traditional 3CG vaccination has now been found to give varying levels of protection depending upon geographic regions.
Consequent to these factors, many investigators including the WHO recommend that early diagnosis of TB should be considered as a priority area of research and development.
Mycobacteria are powerful iamunogens* for man and aniaalβ, as evidenced by their use in immuno adjuvants to boost iaaune responses. Thus, many antigens derived from M.tuberculosis have been known to induce the formation of specific antibodies and proliferative lymphocytes among TB patients (Ivanyi et al., 1988) and experimental animal models. The detection of an antibody response in TB has a potential application in early diagnosis. Likewise, the study of M.tuberculosis specific T lymphocytes has application in early diagnosis by skin tests and development of protective vaccines.
Thus the focus of research in TB pertaining to these aspects lies in the identification and synthesis of M.tuberculosis specific antigens.
SUBSTITUTESHEET
4. Prior Art
Many investigators have identified protein antigens of M.tuberculosis which have potential immuno diagnostic or immuno prophylatic application. The N-terminal and internal amino acid sequences of many of these antigens have been published. The N-terminal amino acid sequences of some of these are presented in Table 1.
Table I: M.tuberculosis protein antigens identified by N-terminal amino acid sequences.
Investigators Antigens and N-terminus
Shinnick et al, 1987 65 kDa R G C R H P V Ya aguchi et al, 1987 MPB 57 M A K F N I K P L Pattorroyo et a^, 1987 13 kDa A V N I
18 kDa G D L V G P G A E 23 kDa A P K T Y 30 kDa F S X P G L 68 kDa W M T M T 77 kDa G K X I A Y D G A A
Matsuo et al, 1988 30 kDa F S R P G L P Ashbridge et al, 1989 19 kDa E H R V K R G L T V Baird et al, 1989 10 kDa A K V N I P K P Garcia et al, 1989 70 kDa F Q R I T R Q D L L Borremans et al, 1989 32 kDa F S R P G L P
To our knowledge, none of these antigens have been introduced as immuno diagnostic test products. Two of these antigens (10 kDa of Baird et al, 1989 and a homologue of 65 kDa
SUBSTITUTE SHEET
antigen of Shinnick et al, 1987) have been tested for vaccine potency among experimental animal models where they showed poor protection against M.tuberculosis (D.W. Smith, University of Wisconsin, USA, personal communication) .
An ELISA kit for diagnosing TB using A60 antigen present in all mycobacteria has been introduced by ANDA diagnostics (France) . The test is thus not specific for human TB alone.
An alternative method of diagnosis of TB has been the use . of DNA probes. The commercially available GEN PROBE kit (1988) is used to confirm the identity of members of M.tuberculosis complex isolated in culture and has not been used directly on clinical specimen. A positive result with this test does not rule out other mycobacteria. The DNA probe devised by Enzo Biochem (J.Clin Microbiol.1988, Dec) used specific DNA sequences of 1000 bases or aore in length and claimed to be more specific. A major handicap of all DNA based probes is that whether a true positive reaction can be obtained with specimens of patients so as to avoid the laborious culture of bacilli.
Phenotypic variation in virulence is known among the M.tuberculosis strains isolated in South India (Naganathan et al 1987), the molecular basis for which is not yet established. Abou Zeid et al, (1988) found that a 13 kDa protein antigen was present in phage type II virulent
M.tuberculosis and absent in phage type I South Indian low virulent M.tuberculosis. However, the relationship between this antigen and virulence is yet to be investigated in detail.
SUBSTITUTESHEET
5. The Invention :
A 17 kDa protein antigen was found to be present among the isolates of M.tuberculosis. The iπmuno chemical features of this antigen are disclosed under this invention.
Thus the present invention relates to:
1. The 17 kDa protein antigen of M.tuberculosis (SII 1) as defined below and certain sub structures (peptides) of 17 kDa protein antigen as defined below.
2. A DNA sequence coding for the 17 kDa antigen from M.tuberculosis (SII 1).
3. A DNA sequence coding for the sub structures (peptides) of the 17 kDa antigen from M.tuberculosis (SII 1),
4. The use of the said 17 kDa protein or the said sub structures (peptides) for the preparation of monoclonal or polyclonal antisera which react with the said 17 kDa protein antigen or sub structures thereof. The said antibodies can be raised in aammals like mice, rabbits and goats for polyclonals and in aice for aonoclonals.
5. The use of the said 17 kDa protein antigen of the said sub structures (peptides) for the detection of antibodies among human and aniaal specimen for iaauno-diagnosis. Detection methods are known in the art one employs such as ELISA, radio immuno assay (RIA) and reverse passive hemagglutination
(RPHA).
SUBSTITUTESHEET
6. The use of the 17 kDa protein antigen or sub structures (peptides) thereof for the treatment of tuberculosis.
7. The use of the 17 kDa protein antigen or substructures peptides thereof for the preparation of a vaccine against tuberculosis.
8. The use of the 17 kDa antigen or sub structures (peptides) thereof for the preparation of a reagent for the skin test in immuno diagnosis for tuberculosis.
9. DNA or RNA probes constructed on the basis of the protein sequence of the 17 kDa antigen or sub structures (peptides) thereof for diagnosis of tuberculosis. Such probes can be constructed by methods known in the art. Labelling of such probes can be done by known methods such as radioisotope incorporation or by non radio-active labelling use for example, biotin.
10. A method of diagnosis of human tuberculosis by interacting body fluids such as serum, CSF, pleural fluids from a patient to be diagnosed with a monoclonal antibody to the 17 kDa antigen or its sub structures (peptides) as defined in paragraph 3 above.
11. A method for diagnosis of human tuberculosis by interacting a body fluid such as serum from a patient to be diagnosed with a 17 kDa protein as defined in paragraph 5 above.
12. A method of diagnosing human tuberculosis by interacting body fluids such as sputum, serum, CSF and pleural fluids
SUBSTITUTE SHEET
from a patient to be diagnosed with a DNA or RNA probe as defined in paragraph 9 above.
13. A method for in vitro detection of human tuberculosis which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a monoclonal antibody as defined in paragraph 10 in labelled form.
14. A method for in vitro detection of human tuberculosis, which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a monoclonal antibody as defined in paragraph 10 in labelled form.
15. A method for in vitro detection of human tuberculosis, which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a polyclonal antibody as defined in paragraph 3 in labelled form.
16. A kit for performing immuno diagnosis of tuberculosis utilizing a monoclonal antibody to 17 kDa antigen as disclosed in paragraph 3 above.
17. A kit for immuno diagnosis of tuberculosis utilizing 17 kDa antigen or peptide sub structures as disclosed in paragraph 5 above.
18. A kit for diagnosing tuberculosis utilizing a DNA or RNA probes as disclosed in paragraph 9 above.
19. A micro organism expressing a 17 kDa protein or sub structures thereof as disclosed in paragraph 1 above.
20. A vaccine against tuberculosis developed on the basis of the 17 kDa antigen or sub structure peptides thereof as disclosed in paragraph 1 above. Such a vaccine can be a product of genetically engineered organisms such as Salmonella, Vaccinia virus etc.
The present invention is exemplified by but not limited to the diagnosis, therapy or prophylaxis of diseases, especially diagnosis of M.tuberculosis infection. Epidemiological screening, forensic investigations, determination of food contaminations, public health surveys, preventive medicine, veterinary and agricultural applications with regard to the diagnosis of infectious agents may be covered by this disclosure.
5.1 Fractionation and purification of 17 kDa antigen.
5.1.1 Crude sonicate antigen. o M.tuberculosis (SII 1) was cultured at 37 C for 2 weeks in
Kirchner's medium and harvested bacilli were killed in cold o acetone for 16 h at 4 C. The bacilli were washed thrice with saline and a suspension of 10 g bacilli in 5 ml saline was sonicated at 40 watts output using a miniprobe of a
Branson sonifier. The sonicate was centrifuged at 20,000 x g for 30 min and the supernatant was estimated for protein o content (Lσwry's method) prior to freeze storage at -70 C.
5.1.2 Fractionation and purification.
500 ug of crude sonicate was fractionated on 12.5% sodium dodecyl sulfate polyacrylaaide gel as described by
SUBSTITUTE SHEET
Hunkapiller and Lujan (1986). The protein bands were visualized by brief staining with coomassie brilliant blue and the 17 kDa antigen was electroeluted against 0.05 M ammonium bicarbonate with 0.1% SDS followed by electro- dialysis against 0.01 M ammonium bicarbonate with 0.02 % SDS. The eluted protein was then extracted with chloroform- methanol to remove SDS and the precipitate was dried.
The purity of the eluted protein was analysed by subjecting 5 ug of this precipitate to HPLC using Lichrosorb RP 18 column (LKB) . A single peak eluted at 45% B and 26 min was found to contain immuno reactive antigen. Fig. 1 shows the HPLC profile of 17 kDa antigen.
5.2 Amino acid sequence analysis of 17 kDa antigen
5.2.1 Peptide mapping of 17 kDa antigen
Tryptic map: 30 ug of 17 kDa protein was digested with TPCK treated trypsin with an enzyme to substrate ratio of 1:50 in o 0.1 M ammonium bicarbonate buffer, pH 7.8 at 37 C for 5 h. The tryptic digest was fractionated by HPLC on RP 18 column (0.46 x 25 cm) equilibrated with solvent A (0.1% TFA in water) and the peptides were eluted with a gradient of solvent B (70% acetonitrile containing 0.085% TFA) from 0 to 65% in 60 ain. The tryptic aap is shown in Fig. 2.
V8 protease aap: 30 ug of 17 kDa antigen was treated with o staphylococcal V8 protease for 48 h in 0.07% ammonia at 37
C. The molar ratio of the enzyme to substrate was 1:25. The various peptides in the enzyme digest were purified on an
HPLC column uder the conditions used for tryptic mapping.
The peptide profile is shown in Fig. 3.
SUBSTITUTE SHEET
5.2.2 Sequence analysis of 17 kDa antigen
The amino acid sequence analysis of the protein and the peptide was done using protein sequencer model 77A (Applied Biosyβtems Inc., USA) with an on line PTH amino acid analyser. The sample was solubilized in 10% formic acid and fixed onto a polybrene coated (1 g) TFA treated glass fibre disc and used for sequencing.
The first 18 amino acids from the N-terminal was determined using the whole protein. Based on the amino acid sequences of the tryptic peptides, V8 protease was selected to generate the peptides that could give the overlaps for the tryptic peptides. The alignment of both tryptic and V8 protease peptides gave the complete sequence for the 17 kDa antigen. The details of the overlaps are given in Fig. 4.
5.2.3 Amino acid composition of 17 kDa antigen
The protein has A9, C3, Dll, E10, F9, G8, H2, 17, K4, Lll, M2, P9, Q2, R12, 88, T9, Vll and Y4. It is significant in not having tryptophan and aβparagine. The protein is acidic in nature since it has 5 acidic aain acids (D+E-21) in excess of the total number of basic aaino acids (R+K-16) .
The protein has 131 aaino acids that account for a molecular weight of 14,762.
5.3 Immuno reactivity of 17 kDa antigen
5.3.1 Demonstration that 17 kDa antigen is iamunodoβinant in M. tuberculosis strains.
M. tuberculosis (SII 1) , M. tuberculosis ATCC 27294, H.phlei, M^
SUBSTITUTE SHEET
smegmatis, M.kanasasli, M.avium intracellulare and M.scrofulaceu were cultured in Kirchner'β medium for 2 weeks and harvested bacilli were killed in cold acetone. Sonicate antigens were prepared from each of these species as described in section 5.1.1. SDS PAGE analysis of these antigens was then carried out in 12.5% gel. Coomassie blue stained gels showed that the 17 kDa antigen was present only in M.tuberculosis strains. A rabbit antiserum raised to M.tuberculosis SII 1 was also used to probe these sonicates in Western blotting. The dominant 17 kDa band was found in the Wes¬ tern blot.
5.3.2 Demonstration that 17 kDa elicits antibodies among experimental animals.
Electro eluted 17 kDa antigen (10 ug in 100 ul saline) was emulsified with an equal volume of Freund's incomplete adjuvant (FICA) and used for intra peritoneal immunization of 10 BALB/c mice. Serua collected froa these aice 30 days after immunization recognized a 17 kDa band in the sonicate antigen of M.tuberculosis SII 1.
Thus this experiment confirms that a polyclonal or monoclonal antibody can be produced in the mouse which recognize the protein structure of 17 kDa antigen or sub structures (peptides) thereof. Such antibodies, in particular the monoclonal antibodies can be used in an antigen detection method like the sandwich ELISA for the detection of the 17 kDa antigen or sub structures thereof among human tuberculosis specimen leading to immuno diagnosis of tuberculosis.
SUBSTITUTE SHEET
5.3.3 Demonstration that 17 kDa antigen reacts with human TB patient sera.
Sera derived from 24 healthy persons and 20 culture proven TB patients were titrated against the 17 kDa antigen as follows.
PVC Dynatech plates were coated with 1 ug/ l PBS of electro o eluted 17 kDa antigen for 24 h at 22 C. PBS-BSA blocked plates were then titrated against duplicate (1/200) dilutions o of sera which were incubated at 22 C for 2.5 h. Washed plates received anti human IgG HRP conjugate for 1.5 h.
Washed plates were then assayed with O-phenylene diamine substrate and read at 492 na. Table II shows that the 17 kDa antigen had a sensitivity of 70% and specificity of 85%
Table II. Micro ELISA with 17 kDa antigen on sera from TB patients and controls
Serum groups n ELISA + ELISA- Sensitivity Specific!
Healthy people 24 4 20 — 85% TB patients 20 14 6 70%
Sensitivity: Known positivity among TB patients Specificity: Known negativity among healthy controls ELISA + : OD 492 n >-0.3 at 1/200 dilation (-mean + 2SD of OD 492 na for healthy controls, n-24].
Thus this experiment confirms that the 17 kDa antigen from
M.tuberculosis strains can be used in a micro ELISA system for the immuno diagnosis of tuberculosis in man.
5.3.4 Demonstration that the 17 -kDa protein antigen has defined antibody epitopes
The peptide fragments derived from the 17 kDa antigen by tryptic digestion (section 5.2.1, Fig.2) were individually
SUBSTITUTE SHEET
titrated against sera from healthy persons and TB patients as in section 5.3.3. Of the 14 peptides tested, peptides with the sequences RATYDK, YEVR, LEDEMK, LMR, DFDGR and SEFAYGSFVR showed antibody binding activity with sensitivity levels between 17 to 36%. To determine whether these peptides formed linear or conformational antibody epitopes, an inhibition of ELISA was carried out in which each of the peptide was assayed against the other five using the mouse antiserum to 17 kDa antibody. The peptides YEVR and ATYDK were mutually inhibitive thus indicating that they were a part of a complete antibody epitope, which was confirmed also by the determination of the complete structure of the 17 kDa antigen as in section 5.2.2, Fig 4. The other four _peptides were linear and probably conformational in the presentation of the antibody epitope. Of the said six antibody epitope bearing peptides, the peptides of the following aaino acid sequences were synthesized by solid phase aethod of
Merrifield and were found to contain specific and sensitive antibody binding activities :
RATYDKRYEVR : Sensitivity 65%; Specificity 95%
SEFAYGSFVR : Sensitivity 66%; Specificity 95*
The antibody epitope mapping as described has thus indicated that defined sub structures or peptides of 17 kDa antigen can be synthesized and used for the immunodiagnosis of human tuberculosis in micro ELISA.
The peptide of the sequence RATYDKRYEVRDFDGRAEL was synthesized and found to have a sensitivity of 86.6% and a specificity of 100% when tested on CSF samples from culturtproven TBM patients and controls. This peptide is accordingly particularly suitable for use in place of the 17 kDa antigen in the ELISA test.
5.3.5 Demonstration that 17 kDa antigen is lympho proliterative
Peripheral blood lymphocytes (PBL) from healty donors and TB
6 patients were fractionated and 2 x 10 cells were cultured in presence or absence (control) of 1 ug of 17 kDa antigen for 3 days in RPK1 1640 medium with 10% autologous serum. 24 h before harvesting cultures were pulsed with 1 uCi of 3H thymidine. Table III shows that the 17 kDa antigen was lympho proliterative to the lymphocytes of TB patients (data shown for 2 persons only) .
Table III. Lympho proliferative assay with 17 kDa antigen.
Source (PBL) 3H thymidine incorporation (cp , aean of triplicate cultures)
Healthy Control : 90 Antigen : 121
TB patient Control : 110 Antigen : 650
In addition to the lympho proliferative property of the 17 kDa antigen, a method of prediction of T cell stimulatory epitopes (Rothbard and Taylor, 1988) was used to map the probable sites in the structure of the 17 kDa antigen. These T cell epitopes were located on peptides of the following sequences: SEFAYGSFVR AELPGVDPDCDVCITK
Thus this experiment indicates that the 17 kDa antigen or sub structures (peptides) can te used to stimulate human peripheral blood lymphocytes. Since stimulated lymphocytes
elaborate several cellular growth and differentiation factors which contribute to the vaccine effect of 17 kDa antigen or its sub structures, the 17 kDa antigen can be used at the first instance as a vaccine against TB and also for non- specifically boosting cellular immunity.
Figure 6 shows the primary structure of the 17 kDa antigen from M.tuberculosis containing the biologically active regions, although similar activity need not be ruled out in the unmarked regions.
6. Discussion and summary of test results
The present invention describes the immunoche ical properties of a novel 17 kDa protein antigen from M.tuberculosis (SII 1 strain) . M.tuberculosis causes tuberculosis worldwide aaong 16 million people. Because of inadequacy of the diagnostic procedures available now the disease has not yet been eradicated. The focus of research in recent years has been the development of immuno diagnostic methods for detecting TB at an early stage as well identification of suitable candidates for vaccination since the traditional BCG vaccine has given only a partial protection against TB.
The studies described in this invention show that a novel 17 kDa antigen derived from M.tuberculosis has antigenic activity. Its antigenic nature and chemistry were investigated. The biologically active proteins of the protein antigen were mapped and immuno diagnostic methods were developed for the early detection of TB.
Thus the 17 kDa protein antigen which had 131 aaino acids was found to contain two peptides of sequence RATYDKRYEVR and
SUBSTITUTE SHEET
SEFAYGSFVR which carried antibody binding epitopes for diagnosis of TB. Further, it contained two peptides which carried predicted T cell stimulating regions in sequences, SEFAYGSFVR and AELPGVDPDCDVCITR. The latter two peptides presumably contributed to the T cell stimulating property of the whole 17 kDa antigen described in this invention. The T cell stimulating property of the 17 kDa antigen and its sub structure peptides means that they could be used in therapy and vaccination for TB. 7. Figure legends.
Fig. 1. HPLC analysis of the electro eluted 17 kDa protein antigen from M. tuberculosis (SII 1).
HPLC conditions: RP 18 column (LKB, 10 um pore size), A: 0.1% TFA in water, B: 0.085% TFA in 70% aceto nitrile, Gradient: 0 to 65% B in 40 min. Sensitivity: 0.08,220 nm.
Fig. 2. Tryptic peptides of 17 kDa protein antigen from
M.tuberculosis (SII 1) fractionated by HPLC on RP 18 (LKB,10 um pore size).
Fractionation: A: 0.1% TFA in water, B: 0.085% TFA in 70% aceto nitrile, Gradient: 0 to 65% B in 60 min. Sensitivity:
0.08, 220 nm.
Amino acid sequence: Sequence determined are drawn against each peptide.
Fig. 3. V8 protease peptides of 17 kDa protein antigen from M.tuberculosis (SII 1) fractionated by HPLC on RP 18 (LKB, pore size 10 um) .
Fractionation: A: 0.1% TFA in water; B: 0.085% TFA in 70% aceto nitrile. Gradient: 0 to 65% in 60 min. Sensitivity: 0.082,220 nm.
Fig. 4. The primary structure of the 17 kDa antigen of
M.tuberculosis (SII 1) showing the alignment of peptides. Trp:
Trypsin, V8: Staphylococcus aureus V8 protease. Superscript
SUBSTITUTE SHEET
arrows denote the amino acid sequence obtained with the whole protein.
(Single letter code used for amino acids).
Fig. 5. The primary structure of the 17kDa antigen from
M.tuberculosis (SII 1) showing the biologically active regions.
AA 68 to 77: Antibody and T cell epitopes present.
AA 91 to 101: Antibody epitope present.
AA 107 to 122: Two T cell epitopes present.
8. References
1. A.Hopps and E.J. Woods, Proc.Natl.λcad.Sciences, (1981) 78,3429
2. Hunkapiller, M,W and Lujan E, In, Methods in Protein Microcharacterization, Ed.J.E. Shiveley, Humana Press (1986) pp.89
3. Naganathan, N, etal. Tubercle (1986) 67,261
4. Shinnick,F, et al, J.Bacteriol, (1987) 169,1080
5. Yamaguchi, Y, etal, FEBS Letters, (1987) 240,115
6. Pattorroyo G, et al, Modern Biotechnology in Health, Academic press, (1987), pp.110.
7. Ivanyi, J et al, Springers Seminars Imaunopathol, (1988)10 279
8. Abou-Zeid etal, J.Gen Microbiol (1988) 134,531
9. Matsuo M etal, J.Bacteriol, (1988) 170, 3847
10. Rothbard, J,B and Taylor, W, EMBO J (1988) 7,93
11. Ashbridge S, etal, Nucleic Acids Res (1989) 17,1249
12. Boremans et al. Infection and Immunity, (1989) 57, 3123
13. Garcia E, etal (1989) Infection and Immunity (1989) ,57,204
14. Baird et al, J.Gen Microbiol, (1989)135, 931.
SUBSTITUTE SHEET
Claims
1. The protein of the structure:
1 40
ATTLPVQRHPRSLFPEFSELFAAFPSFAGLRPTFDTREI_M
80 RSIQITIKLEDEMKGIYLPVAKHGELRSEFAYGSFVRTVS
131 LPVGADEDDIRATYDKRYEVRDFDGRAELPGVDPDCDVCITRGILTVSVσV
2. Peptides of the structure:
RATYDKRYEVRDFDGRAEL
AELPGVDPDCDVCITR and fragments of the protein according to claim 1 which include one or more of these peptide sequences.
3. A DNA sequence coding for the protein defined in claim 1.
4. A DNA sequence coding for peptides defined in claim 2.
5. A DNA or RNA hybridization probe, constructed on the basis of the proteins or peptides defined in claim 1 or 2 or on the basis of DNA sequences according to claim 3 or 4, said probe being optionally labelled.
6. An antibody to a protein or peptide as defined in claim 1 or 2.
7. An antibody according to claim 6 which is a polyclonal or a monoclonal antibody, said antibody being optionally labelled.
8. A kit for performing iaauno diagnosis of tuberculosis including a protein or peptide according to claim 1 or 2.
SUBSTITUTE ^
9. A kit for performing immuno diagnosis of tuberculosis including a monoclonal antibody according to claim 7.
10. A kit for performing DNA based diagnosis of tuberculosis including a hybridization probe according to claim 5.
11. A microorganism capable of expressing a protein or peptide according to claim 1 or 2.
12. A vaccine against tuberculosis including a protein or peptide according to claim 1 or 2.
13. A method of diagnosis of human tuberculosis which comprises interacting body fluids such as serum from a patient with a protein or peptide according to claim 1 or 2.
14. A method of diagnosis of human tuberculosis which comprises interacting body fluids such as sputum, CSF, pleural fluid or serαm from a patient with a monoclonal antibody according to claim 7 in labelled form.
15. A method of diagnosis of human tuberculosis which comprises interacting body fluids such as sputum, CSF, pleural fluid or serum from a patient with a DNA probe according to claim 5 in labelled form.
16. An In YUJ__2 method for detection of human tuberculosis, which comprises contacting a sample of a body fluid such as sputua, CSF, pleural fluid or serum from a patient with a polyclonal antibody according to claim 7 in labelled form.
17. An in vitro method for detection of human tuberculosis, which comprises contacting a sample of a body fluid such as sputum, CSF, pleural fluid or serum from a patient with a monoclonal antibody according to claim 7 in labelled form.
18. A protein or peptide according to claim 1 or 2 for use in a method of treatment of the human or animal body in immuno-diagnosiβ, therapy or vaccination in relation to human tuberculosis.
19. A protein or peptide according to claim 1 or 2 for use in a method of treatment of the human or animal body for producing mammalian polyclonal antibodies or monoclonal antibodies in mice for use in an ircmunodiagnostic method like sandwich ELISA which detects the protein according to claim 1 among human tuberculous specimens.
20. A protein or peptide according to claim 1 or 2 for use in a method of treatment of the human or animal body for the detection of antibodies among tuberculous specimens by serological methods for early detection of tuberculosis.
21. A protein or peptide according to claim l or 2 or use in a method of treatment of the human or animal body for the detection of T cell proliferation in a tuberculous specimen for obtaining immuno diagnosis through skin tests or obtaining a candidate for vaccine against tuberculosis.
22. Use of a protein according to claim 1 or 2 for im uno-diagnosis, therapy and vaccination in relation to human tuberculosis.
SUBSTITUTE SHEET
23. Use of a protein or peptide according to claim
•r
1 or 2 for developing a reagent for therapy of tuberculous inflammation by T cell proliferation.
24. Use of a protein or peptide according to claim 1 or 2 for the production of growth and differentiation factors using T cell proliferation assay.
25. The use of DNA or RNA probes according to claim 5 for detection of M.tuberculosis DNA among human tuberculous specimen for early detection of tuberculosis.
26. The use of DNA or RNA probes according to claim 5 for the purposes of identification of mycobacterial DNA for example among cultural isolates and for laboratory research.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR919105237A BR9105237A (en) | 1990-03-27 | 1991-03-22 | PROTEINS, PEPTIDES, DNA SEQUENCES, DNA OR RNA HYBRIDIZATION EVIDENCE, ANTIBODY, TUBERCULOSIS IMMUNE DIAGNOSIS, MICROORGANISM, TUBERCULOSIS VACCINE, PROCESS FOR TUBERCULOSIS TUBERCULOSIS TUBERCULOSIS |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9001105A SE9001105D0 (en) | 1990-03-27 | 1990-03-27 | NEW METHODS FOR DIAGNOSIS OR TUBERCULOSIS |
| SE9001105-7 | 1990-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991014448A1 true WO1991014448A1 (en) | 1991-10-03 |
Family
ID=20379003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SE1991/000225 WO1991014448A1 (en) | 1990-03-27 | 1991-03-22 | New proteins, peptides and corresponding dna or rna sequences and probes useful for diagnosing tuberculosis |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0479971A1 (en) |
| CN (1) | CN1060310A (en) |
| AU (1) | AU7564491A (en) |
| BR (1) | BR9105237A (en) |
| IL (1) | IL97572A0 (en) |
| JO (1) | JO1671B1 (en) |
| PT (1) | PT97150A (en) |
| SE (1) | SE9001105D0 (en) |
| WO (1) | WO1991014448A1 (en) |
| ZA (1) | ZA911855B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
| US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6338852B1 (en) | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6465633B1 (en) | 1998-12-24 | 2002-10-15 | Corixa Corporation | Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis |
| US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
| US6761894B1 (en) | 1993-11-23 | 2004-07-13 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103063836B (en) * | 2011-10-18 | 2016-03-30 | 复旦大学附属华山医院 | Detect the reagent of mycobacterial infections, method and kit |
| CN111518165B (en) * | 2020-05-08 | 2021-10-01 | 宁夏大学 | Polypeptide specifically binding to mycobacterium tuberculosis, coding gene and application thereof |
| CN112125954B (en) * | 2020-09-28 | 2023-02-28 | 宁夏医科大学总医院 | Heptapeptide specifically combined with BCG (bacillus calmette guerin), coding gene, preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988005823A2 (en) * | 1987-02-02 | 1988-08-11 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes encoding protein antigens |
| WO1988006591A1 (en) * | 1987-02-26 | 1988-09-07 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
-
1990
- 1990-03-27 SE SE9001105A patent/SE9001105D0/en unknown
-
1991
- 1991-03-13 ZA ZA911855A patent/ZA911855B/en unknown
- 1991-03-15 IL IL97572A patent/IL97572A0/en unknown
- 1991-03-21 JO JO19911671A patent/JO1671B1/en active
- 1991-03-22 BR BR919105237A patent/BR9105237A/en unknown
- 1991-03-22 WO PCT/SE1991/000225 patent/WO1991014448A1/en not_active Application Discontinuation
- 1991-03-22 AU AU75644/91A patent/AU7564491A/en not_active Abandoned
- 1991-03-22 EP EP91906940A patent/EP0479971A1/en not_active Withdrawn
- 1991-03-26 PT PT97150A patent/PT97150A/en not_active Application Discontinuation
- 1991-03-27 CN CN91101235A patent/CN1060310A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988005823A2 (en) * | 1987-02-02 | 1988-08-11 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes encoding protein antigens |
| WO1988006591A1 (en) * | 1987-02-26 | 1988-09-07 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
Non-Patent Citations (4)
| Title |
|---|
| Infection and Immunity, Vol. 55, No. 12, December 1987 ANNE WORSAAE et al.: "Allergenic and Blastogenic Reactivity of Three Antigens from Mycobacterium tuberculosis in Sensitized Guinea Pigs", see page 2922 - page 2927. * |
| Journal of Clinical Microbiology, Vol. 24, No. 1, July 1986 S.R. COATES et al.: "Identification fo Mycobacterium tuberculosis Antigens in Seibert Fractions by Immunoblotting", see page 126 - page 130. * |
| Journal of Clinical Microbiology, Vol. 26, No. 12, December 1988 ANNE WORSAAE et al.: "Monoclonal Antibodies Produced in BALB.B10 Mice Define New Antigenic Determinants in Culture Filtrate Preparations of Mycobacterium tuberculosis", see page 2608 - page 2614. * |
| Journal of Immunology, Vol. 138, No. 3, February 1987 FREDRIK OFTUNG et al.: "Human OFTUNG et al.", see page 927 - page 931. * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
| US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US6761894B1 (en) | 1993-11-23 | 2004-07-13 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6338852B1 (en) | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6949246B2 (en) | 1995-09-01 | 2005-09-27 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6962710B2 (en) | 1995-09-01 | 2005-11-08 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US7122196B2 (en) | 1995-09-01 | 2006-10-17 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US7238358B2 (en) | 1995-09-01 | 2007-07-03 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
| US6465633B1 (en) | 1998-12-24 | 2002-10-15 | Corixa Corporation | Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis |
Also Published As
| Publication number | Publication date |
|---|---|
| IL97572A0 (en) | 1992-06-21 |
| CN1060310A (en) | 1992-04-15 |
| AU7564491A (en) | 1991-10-21 |
| ZA911855B (en) | 1991-12-24 |
| EP0479971A1 (en) | 1992-04-15 |
| SE9001105D0 (en) | 1990-03-27 |
| JO1671B1 (en) | 1992-08-09 |
| PT97150A (en) | 1991-12-31 |
| BR9105237A (en) | 1992-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wiker et al. | The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis | |
| Triccas et al. | A 35-kilodalton protein is a major target of the human immune response to Mycobacterium leprae | |
| AU614004B2 (en) | Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions | |
| JP2007000147A (en) | Peptide fragment of microbial stress protein and use of the protein or fragment | |
| KR20010012813A (en) | Compounds for diagnosis of tuberculosis and methods for their use | |
| Roche et al. | T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of Mycobacterium bovis | |
| JPH07508498A (en) | Staphylococcus epidermidis-associated type I and II surface antigens | |
| JP3747057B2 (en) | Bacterial stress protein | |
| CN107216373B (en) | Antigen polypeptide pool for detecting mycobacterium tuberculosis infection and application thereof | |
| CN107011418B (en) | Antigen polypeptide pool for detecting mycobacterium tuberculosis infection and application thereof | |
| WO1991014448A1 (en) | New proteins, peptides and corresponding dna or rna sequences and probes useful for diagnosing tuberculosis | |
| AU2002237764B2 (en) | Latent human tuberculosis model, diagnostic antigens, and methods of use | |
| Triccas et al. | Molecular and immunological analyses of the Mycobacterium avium homolog of the immunodominant Mycobacterium leprae 35-kilodalton protein | |
| WO2013075608A1 (en) | Chimeric recombinant antigen and use thereof | |
| AU2002237764A1 (en) | Latent human tuberculosis model, diagnostic antigens, and methods of use | |
| US6517838B1 (en) | Decorin binding protein essential peptides and methods of use | |
| US7169393B2 (en) | Antigenic peptide fragments of VapA protein, and uses thereof | |
| CN107141341B (en) | Antigen polypeptide pool for detecting mycobacterium tuberculosis infection and application | |
| GB2239246A (en) | Protein antigen from Mycobacterium tuberculosis | |
| US5254459A (en) | Nucleotide and amino acid sequences of protein MTP40 of M. tuberculosis and synthetic peptides derived therefrom | |
| US5460813A (en) | Method for treating Kawasaki syndrome by administration of an anti-TSST-1 agent which is not gamma globulin | |
| US5171839A (en) | Nucleotide and amino acid sequences of protein mtp40 of m. tuberculosis and synthetic peptides derived therefrom | |
| JPS61185183A (en) | Hybrid cell system for producing cell lytic monoclonal antibody to vagina trichomonas | |
| US5169940A (en) | Nucleotide sequences of protein MTP40 of M. tuberculosis | |
| AU707298B2 (en) | Broadly reactive opsonic antibodies reactive with common staphylococcal antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1991906940 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1991906940 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1991906940 Country of ref document: EP |